Cue Biopharma to present new preclinical data on CUE-401 at IMMUNOLOGY2026
Share
Listen to the news
Cue Biopharma to present new preclinical data on CUE-401 at IMMUNOLOGY2026
  • Cue Biopharma scheduled presentation of new preclinical data on lead autoimmune and inflammatory disease candidate CUE-401 at IMMUNOLOGY2026 in Boston, April 15-19, 2026.
  • Results will be presented in a poster session on April 18, 2026, 11:30 a.m.–12:30 p.m. EDT.
  • Data support CUE-401 potential to drive expansion of functional, stable FOXP3+ regulatory T cells from conventional CD4+ T cells, positioning program as a possible approach to restore immune balance in autoimmune and inflammatory disease.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cue Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604150800PRIMZONEFULLFEED9689765) on April 15, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending